Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azvudine in Mild COVID-19
NCT05033145Phase 3Completed
- Sponsor
- HRH Pharmaceuticals Limited
- Start
- Jan 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Azvudine Arm with Placebo Arm (2 arms). Primary endpoints: Proportion of patients hospitalized during the study and Proportion of participants with a clinical outcome of CURE. Started Jan 2022; status: completed.
02
Drugs
azvudine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05033145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05033145.